Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc.

NNASDAQ:VVOS
0.08
USD
-0.02
(-16.12%)
-1.95EPS
6.13MMarket Cap
Nov 18Next Earn

Total Valuation

USD

As of June 30, 2026, Vivos Therapeutics, Inc. carries a market capitalization of 6.13M, placing it among publicly traded companies globally. Its enterprise value stands at 17.79M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap6.13M
Enterprise Value17.79M

Important Dates

Vivos Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 18, 2026.

Earnings Date11/18/2026

Share Statistics

As of June 30, 2026, Vivos Therapeutics, Inc. has 13.49M shares outstanding.

Shares Outstanding13.49M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 0.29, and the price-to-book ratio stands at -1.25.

PS Ratio0.29
PB Ratio-1.25
P/TBV Ratio-0.36
P/FCF Ratio-0.31
P/OCF Ratio-0.35

Enterprise Valuation

These figures are as of June 30, 2026. The EV/Sales ratio of 0.85 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 17.79M versus a market cap of 6.13M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales0.85

Financial Position

As of June 30, 2026, Vivos Therapeutics, Inc. maintains a current ratio of 0.21, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities.

Current Ratio0.21
Quick Ratio0.16
Debt / Equity-313.72
Debt / EBITDA-0.60

Financial Efficiency

USD

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -101.71, reflecting losses generated across the asset base. The company generates approximately 91,570.65 in revenue per employee across its workforce of 228.25, a quick read on workforce productivity versus industry peers.

Return on Assets (ROA)-101.71
Revenue Per Employee91,570.65
Employee Count228.25

Stock Price Statistics

USD

As of the close on November 16, 2026, Vivos Therapeutics, Inc.'s stock has declined approximately 96.49% over the past 52 weeks. The 50-day moving average sits at 0.14, while the 200-day moving average is 0.65.

52-Week Price Change-96.49%
50-Day Moving Average0.14
200-Day Moving Average0.65

Income Statement

USD

Over the twelve months ended June 30, 2026, Vivos Therapeutics, Inc. generated 20.90M in revenue and converted that into -25.52M in net income, yielding earnings per share of -1.95. EBITDA reached -20.76M, while operating income came in at -22.56M.

Revenue20.90M
Gross Profit12.94M
Operating Income-22.56M
Pretax Income-25.63M
Net Income-25.52M
EBITDA-20.76M
EBIT-22.56M
Earnings Per Share (EPS)-1.95

Balance Sheet

USD

As of June 30, 2026, Vivos Therapeutics, Inc. holds 1.77M in cash and equivalents against 12.51M in total debt, resulting in a net debt position of 6.36M. Total book value stands at -4.92M, with working capital of -16.18M providing operational flexibility.

Cash & Cash Equivalents1.77M
Total Debt12.51M
Net Debt6.36M
Equity (Book Value)-4.92M
Book Value Per Share-0.36
Working Capital-16.18M

Cash Flow

USD

Vivos Therapeutics, Inc. produced -17.13M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.88M in capital expenditures, free cash flow totaled -19.01M - equivalent to -1.45 per share.

Operating Cash Flow-17.13M
Capital Expenditures-1.88M
Free Cash Flow-19.01M
FCF Per Share-1.45

Margins

Over the twelve months ended June 30, 2026, Vivos Therapeutics, Inc. posted a gross margin of 61.90, reflecting its pricing power and cost economics. The operating margin of -107.92 and net profit margin of -122.09 provide insight into operational efficiency.

Gross Margin61.90
Operating Margin-107.92
Pretax Margin-122.62
Profit Margin-122.09
EBITDA Margin-99.35

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -318.32: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -268.13, meaning Vivos Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-268.13
FCF Yield-318.32

Stock Splits

Vivos Therapeutics, Inc.'s most recent stock split took place on October 27, 2023 with a 25:1 split ratio.

Last Split Date10/27/2023
Split Ratio25:1

Scores

As of June 30, 2026, Vivos Therapeutics, Inc. has an Altman Z-Score of -22.23, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-22.23